YES, a novel therapeutic target in hepatocellular carcinoma

Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapouge, Marjorie, Meloche, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067521/
https://www.ncbi.nlm.nih.gov/pubmed/35529900
http://dx.doi.org/10.1080/23723556.2022.2069993
Descripción
Sumario:Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies the tyrosine kinase YES as a potential therapeutic target in HCC.

Ejemplares similares